Abstract
Parkinson’s disease is a neurodegenerative disorder that affects approximately 1% of people over the age of 60 years. Levodopa is standard, and often initial, therapy for patients with this condition; however, with continued treatment and as the disease progresses, up to 80% of patients experience ‘wearing-off’ symptoms, dyskinesias and other motor complications. These levodopa-associated problems may become disabling and profoundly affect quality of life. Medications commonly used to manage these symptoms include monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, the NMDA receptor antagonist amantadine and dopamine receptor agonists.
Agents that block MAO-B, such as rasagiline and selegiline, are used as both initial and adjunctive therapy in patients with Parkinson’s disease. These medications increase concentrations of dopamine in the brain by blocking its reuptake from the synaptic cleft, a mechanism that can slow motor decline, increase ‘on’ time and improve symptoms of Parkinson’s disease. Adverse events with these agents can include confusion, hallucination and orthostatic hypotension. MAO-B inhibition may elicit drug-drug interactions if administered with TCAs, SSRIs or serotonin-noradrenaline (norepinephrine) reuptake inhibitors. Conventional oral selegiline is associated with potentially harmful plasma concentrations of three major amfetamine metabolites, although metabolite concentrations are significantly lower with a new orally disintegrating tablet (ODT) selegeline formulation. Selegiline ODT is also absorbed more efficiently and shows less pharmacokinetic variability than conventional oral selegiline.
COMT mediates peripheral catabolism of levodopa. Therefore, agents that block COMT, such as tolcapone and entacapone, increase the elimination half-life of levodopa. Given adjunctively with levodopa, COMT inhibitors can decrease ‘off’ time and increase ‘on’ time, as well as lower the daily levodopa dose. Although more potent than entacapone, tolcapone requires monitoring for hepatotoxicity.
Amantadine is a noncompetitive NMDA receptor antagonist shown to lower dyskinesia scores and improve motor complications in patients with Parkinson’s disease when given adjunctively with levodopa.
Dopamine agonists, also used as initial and adjunctive therapy in Parkinson’s disease, improve motor response and decrease ‘off’ time purportedly through direct stimulation of dopamine receptors. Current dopamine agonists include bromocriptine, pergolide, cabergoline, lisuride, apomorphine, pramipexole, ropinirole and rotigotine. Although effective, this class of medications can be associated with cardiovascular and psychiatric adverse effects that can limit their utility.
All medications used to manage levodopa-associated motor complications in patients with Parkinson’s disease have had differing degrees of success. Although head-to-head comparisons of drugs within classes are rare, some differences have emerged related to effects on motor fluctuations, dyskinesias and on/off times, as well as to adverse effects. When choosing a drug to treat levodopa-induced complications, it is important to consider the risks and benefits of the different classes and of the specific agents within each class, given the different efficacy and safety profiles of each.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004; 363(9423): 1783–93
Hampton T. Parkinson disease registry launched. JAMA 2005; 293(2): 149
de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5(6): 525–35
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348(14): 1356–64
Jankovic J. Pathophysiology and assessment of parkinsonian symptoms and signs. In: Pahwa R, Lyons KE, Koller WC, editors. Handbook of Parkinson’s disease. 4th ed. New York: Taylor & Francis Group, LLC, 2007: 49–75
Chaudhuri KR, Healy DG, Shapira AH, et al. Non-motor symp- toms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45
Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004; 19(9): 997–1005
Dewey Jr RB. Management of motor complications in Parkinson’s disease. Neurology 2004; 62Suppl. 4: S3–7
Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58Suppl. 1: S19–32
Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20Suppl, 11: S11–6
Marjama-Lyons JM, Koller WC. Parkinson’s disease: update in diagnosis and symptom management. Geriatrics 2001; 56(8): 24–30, 33
Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989; 39Suppl. 2: 11–9
Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20(6): 726–33
Stacy M, Hauser R, Oertel W, et al. End of dose wearing-off in Parkinson’s disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29(6): 312–32
Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005; 20(2): 224–30
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365(9463): 947–54
Jankovic J. An update on the treatment of Parkinson’s disease [Melvin D. Yahr memorial lecture]. Mt Sinai J Med 2006; 73(4): 682–9
Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005; 20Suppl. 11: S3–10
Kurth MC. Using liquid levodopa in the treatment of Parkinson’s disease: a practical guide. Drugs Aging 1997; 10(5): 332–40
Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62(6): 905–10
Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998; 97(3): 175–83
Rao SS, Hofmann LA, Shakil A. Parkinson’s disease: diagnosis and treatment. Am Fam Physician 2006; 74(12): 2046–54
Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. Eur Neurol 2000; 44(1): 22–30
Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63(2): 228–34
Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19(4): 426–32
Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003; 168(3): 293–301
Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 1999; 14(2): 246–51
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62(2): 241–8
Radad K, Gille G, Rausch W-D. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep 2005; 57(6): 701–12
Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease, 2001 to 2004. Mov Disord 2005; 20(5): 523–39
Henchcliffe C, Schumacher HC, Burgut FT. Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 2005; 5(6): 811–21
Dostinex [package insert]. New York; Pfizer Inc, 2004
Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355(9): 896–908
Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section: Pt I. Early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006; 13(11): 1170–85
Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68(4): 272–6
Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline: an update. Clin Pharmacokinet 1997; 33(2): 91–102
Mercuri NB, Scarponi M, Bonci A, et al. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 1997; 17(7): 2267–72
Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006; 66(9): 1427–9
Azilect [package insert]. Kfar Saba; Teva Pharmaceutical Industries Ltd, 2006
Clarke CE. Rasagiline for motor complications in Parkinson’s disease. Lancet 2005; 365(9463): 914–6
Demarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006; 21(10): 1716–21
Shin H-S. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997; 25(6): 657–62
Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson’s disease patients with motor response fluctuations. Clin Neuropharmacol 1991; 14(3): 228–34
Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. Ann Neurol 2002; 51(5): 604–12
Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66: 1200–6
The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993; 328(3): 176–83
Clarke A, Jankovic J. Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease. Therapy 2006; 3(3): 349–56
Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease. Expert Rev Neurother 2005; 5(6): 705–12
Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002; 41(9): 661–80
Fuh J-L, Lee R-C, Wang S-J, et al. Swallowing difficulty in Parkinson’s disease. Clin Neurol Neurosurg 1997; 99(2): 106–12
Zelapar (selegiline hydrochloride) orally disintegrating tablets [package insert]. Costa Mesa (CA); Valeant Pharmaceuticals International, 2006
Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003; 110(11): 1241–55
Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson’s disease. Clin Neuropharmacol 2001; 24(3): 150–7
Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006; 45(2): 109–36
Widnell KL, Cornelia C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 2005; 20Suppl. 11: S30–7
Olanow CW. Tolcapone and hepatotoxic effects. Arch Neurol 2000; 57(2): 263–7
Lew M, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program [abstract no. 1035]. J Neurol Sci 2005; 238Suppl. 1: S363
Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24(5): 295–9
Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 2007; 22 (1): 14-9
Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2000; 15(5): 873–8
Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23(2): 82–5
Verhagen Metman L, Del Dotto P, Blanchet PJ, et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids 1998; 14(1–3): 75–82
Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998; 50(5): 1323–6
Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. Curr Opin Neurol 2003; 16Suppl. 1: S13–9
Bonnet AM, Serre I, Marconi R, et al. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 1995; 10(5): 668–71
Tintner R, Manian P, Gauthier P, et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol 2005; 62(8): 1290–5
Hayashi R, Tako K, Mikashita H, et al. Efficacy of low-dose lisuride infusion in Parkinson’s disease. Intern Med 1998; 37(5): 444–8
Woitalla D, Müller T, Benz S, et al. Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl 2004; 68: 89–95
Guttman M, the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997; 49(4): 1060–5
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49(1): 162–8
Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 1998; 51(4): 1057–62
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342(20): 1484–91
Whone AL, Watts RL, Stoessl AJ, et al. Slower progression in early Parkinson’s disease treated with ropinirole compared with 1-dopa: the REAL-PET study. Ann Neurol 2003; 54(1): 93–101
Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson’s disease. Arch Neurol 2007; 64: 676–82
Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome. Expert Opin Pharmacother 2007; 8(9): 1329–35
Kolls B, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 2006; 29(5): 292–301
Dewey Jr RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58(9): 1385–92
Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology 2004; 62(6 Suppl. 4): S12–7
Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356(1): 29–38
Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007; 356(1): 39–46
Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease [letter]. Arch Neurol 2006; 63(2): 298
Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21(4): 524–9
Stocchi F. Pathological gambling in Parkinson’s disease. Lancet Neurol 2005; 4(10): 590–2
Prescrire editorial staff. Hypersexuality due to dopaminergic drugs. Prescrire Int 2005; 14(80): 224
Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003; 61(3): 422–3
Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324(7352): 1483–7
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf 2003; 26(6): 439–44
Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999; 340 (10): 757-63
Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62(3): 381–8
Diamond A, Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev Neurother 2006; 6(8): 1181–97
Acknowledgements
No sources of funding were used to assist in the preparation of this review. Dr Jankovic has acted as a consultant for Allergan, Eisai, Merz and Teva, and has received grants from Allergan, Amersham, Boehringer-Ingelheim, Cergene, Medtronic, Merz, Prestwick, Teva and Schwarz Pharma. Dr Stacy has acted as a consultant for and/or received honoraria and grants from GlaxoSmithKline, Novartis, Boehringer-Ingelheim, Vernalis, EMD Biosciences, Schantz and Schwarz Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jankovic, J., Stacy, M. Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease. CNS Drugs 21, 677–692 (2007). https://doi.org/10.2165/00023210-200721080-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200721080-00005